News

Team characterizes EMH niche


 

Proliferating HSCs

Image by John Perry

Previous studies have shown that hematopoietic stresses—such as myelofibrosis, anemia, and myeloablation—can induce extramedullary hematopoiesis (EMH), in which hematopoietic stem cells (HSCs) are mobilized to sites outside the bone marrow.

The splenic red pulp is known to be a prominent site of EMH in both mice and humans, but not much is known about the EMH niche.

Now, investigators say they have characterized this niche.

They detailed their findings in Nature.

The team used mouse models to examine the expression patterns of 2 known niche cell factors, SCF and CXCL12.

They discovered that the hematopoietic microenvironment in the spleen is found near sinusoidal blood vessels and is created by endothelial cells and perivascular stromal cells, just like the microenvironment in the bone marrow.

“Under emergency conditions, the endothelial cells and perivascular stromal cells that reside in the spleen are induced to proliferate so they can sustain all the new blood-forming stem cells that migrate into the spleen,” explained study author Sean Morrison, PhD, of the University of Texas Southwestern Medical Center, Dallas.

“We determined that this process in the spleen is physiologically important for responding to hematopoietic stress. Without it, the mice we studied could not maintain normal blood cell counts during pregnancy or quickly regenerate blood cell counts after bleeding or chemotherapy.”

The investigators believe these findings could aid the development of therapeutic interventions to enhance blood formation following chemotherapy or HSC transplant and thus accelerate the recovery of blood cell counts.

Recommended Reading

Haplo-HSCT appears comparable to fully matched HSCT
MDedge Hematology and Oncology
Imetelstat in MF: More research needed
MDedge Hematology and Oncology
Despite responses, imetelstat won’t move forward in ET
MDedge Hematology and Oncology
Drugs don’t play well together in MF
MDedge Hematology and Oncology
Team reports phase 3 results with abandoned MPN drug
MDedge Hematology and Oncology
Inhibitor could treat range of hematologic disorders
MDedge Hematology and Oncology
Methotrexate could treat MPNs cheaply, team says
MDedge Hematology and Oncology
HSCT outcomes ‘encouraging’ in JAKi responders
MDedge Hematology and Oncology
Agent reduces fibrosis, improves platelet counts in MF
MDedge Hematology and Oncology
JAK inhibitor can provide long-term disease control in PV
MDedge Hematology and Oncology